immunotherapy

July 20, 2017

8 Things to Know About Sarcomatoid Mesothelioma

Sarcomatoid mesothelioma is an extremely rare form of the asbestos-related disease and according to the Mesothelioma Cancer Alliance, it accounts for around 10 percent of all mesothelioma cases. It’s one of three basic types of mesothelioma cell, ... Read more

July 18, 2017

What’s New in Malignant Mesothelioma Research and Treatment?

According to the American Cancer Society, researchers are constantly studying new ways to treat and possibly prevent mesothelioma. However, there is still a lot to be learned about this disease, despite ... Read more

July 5, 2017July 5, 2017

First MPM Patient Dosed in Keytruda, CRS-207 Combo Phase 2 Trial, Aduro Says

News

Aduro Biotech has tested a novel combination treatment for malignant pleural mesothelioma (MPM) in the first patient of a Phase 2 trial (NCT03175172). MPM is the most prevalent form of ... Read more

June 22, 2017

4 Possible Experimental Treatments for Mesothelioma

Mesothelioma is an aggressive cancer that’s mainly caused by an exposure to asbestos. Currently, there is no known cure for the disease but there a number of traditional treatments used to ... Read more

June 21, 2017

Combining Immunotherapy, Accelerated Radiation and Surgery Bolsters Immune Response Against Mesothelioma, Study Shows

News

Combining immunotherapy, accelerated radiation and surgery can improve immune system response against malignant pleural mesothelioma, according to a study. Immunotherapies for solid tumors have become a major focus of cancer research, ... Read more

May 22, 2017May 22, 2017

Bristol-Myers Squibb Recruits Patients for Phase 3 Trial Testing Opdivo-Yervoy Combo to Treat MPM

News

Bristol-Myers Squibb is recruiting 600 participants into a global Phase 3 clinical trial investigating a combination of two immune checkpoint inhibitors — Opdivo (nivolumab) and Yervoy (ipilimumab) — in patients ... Read more

March 21, 2017March 21, 2017

Benefits of Keytruda in Early Pleural Mesothelioma Trial Justifies Further Studies

News

Keytruda (pembrolizumab) may benefit patients with with malignant pleural mesothelioma by targeting tumors that produce the immune checkpoint molecule PD-L1, according to an interim analysis of a Phase 1b study. The treatment ... Read more

February 28, 2017

New Generation of CAR T-cells May Be Effective Against Mesothelioma

News

A new generation of CAR T-cell immunotherapy shows promising results in preclinical models of malignant mesothelioma, prompting researchers to suggest the treatment should be evaluated in clinical trials. In contrast to ... Read more

February 23, 2017

4 Experimental Treatments for Mesothelioma

Mesothelioma is an aggressive cancer which is mainly caused by an exposure to asbestos. Currently, there is no known cure for the disease but there are a number of traditional ... Read more